Shots:
- Milestone Pharma has reported Cardamyst (Etripamil) is now available in the US for paroxysmal supraventricular tachycardia (PSVT); national sales force to be deployed in mid-Feb 2026
- Cardamyst (Intranasal) is a Bidose (BDS) Liquid Nasal Spray System, a self-administered calcium channel blocker nasal spray for rapid response to PSVT, launching with a patient assistance program that offers coverage support, reimbursement help, and copay assistance, capping copays at $25 for eligible commercially insured pts
- Etripamil is in P-II development for pediatric PSVT and P-III development for acute AFib-RVR in adults
Ref: Milestone Pharma | Image: Milestone Pharma | Press Release
Related News: Aptar Reports the US FDA Approval of Cardamyst (Etripamil) for PSVT
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
